Avectas
Avectas develops the Solupore® Integrated platform, a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single consumable. It serves biopharma companies, CDMOs, and academic research institutions worldwide.
- Company typePrivate
- Founded2010
- HeadquartersMaynooth, Ireland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Avectas does
Avectas is a privately held Irish cell engineering technology company headquartered in Maynooth, Ireland, with an additional R&D facility in Dublin and a North American commercial office in Cambridge, Massachusetts. The company develops the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates multiple unit processes (activation, transduction, expansion, and harvest) into a single core consumable, supported by modular Automated Manufacturing Units (AMUs) designed for parallel, scale-out production. The platform also includes the Solupore® Integrated Research Tool (RT) for discovery and translational workflows and the SoluPrime Knock-In Transfection Enhancer as a consumable add-on, with a Drug Master File filed with the FDA and 21 CFR Part 11 electronic batch record compliance for GMP manufacturing customers.
Avectas targets three primary customer segments: enterprise biopharma and cell therapy developers, CDMOs (notably through a strategic channel partnership with CCRM and its subsidiary OmniaBio), and academic and translational research institutions. Its value proposition centers on reducing cell therapy manufacturing economics — claiming 75% facility cost reduction, 600% throughput increase (~350 vs ~50 batches per year), and up to 25% cost-of-goods reduction versus conventional integrated platforms — while improving batch reliability through closed-system automation, inline pH/DO/CO2 sensors, and barcoded chain-of-identity. The company supports non-viral editing workflows including mRNA, CRISPR, and HDR, and is documented to produce >2.5 billion viable cells and >1 billion CD19-CAR+ cells in a 7-day process from 150M CD3+ starting cells.
The company generates revenue through a mix of capital equipment sales (AMUs), recurring consumables (single-use kits for each manufactured batch), and professional services for technology transfer from research use to GMP manufacturing, sold via direct enterprise sales and channel partnerships on multi-year B2B contracts. Total disclosed funding across four rounds between 2018 and 2021 is approximately $38.9M, the largest being a $20M round in April 2020. The scientific advisory board includes prominent figures in cell therapy (Prof. Bruce L. Levine of UPenn, Prof. Mark Lowdell, Prof. Evren Alici), and the company is actively pursuing both US market expansion and CDMO-led distribution channels to scale commercial adoption.
Avectas firmographics
Firmographics- Name
- Avectas
- Legal name
- Avectas
- Website
- https://avectas.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Avectas develops the Solupore® Integrated platform, a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single consumable. It serves biopharma companies, CDMOs, and academic research institutions worldwide.
- Ownership category
- akta.pro rank
Avectas industry classification
Industry- Product category
- Cell Therapy Manufacturing Equipment
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
Keywords
Where Avectas is headquartered
LocationHeadquarters
- HQ city
- Maynooth
- HQ country
- Ireland
- HQ region
- Europe
Offices2 records
Markets served
Avectas business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Solupore Integrated Consumables: Sale of single-use consumable kits for cell therapy manufacturing. The platform is consumable-based, requiring ongoing purchase of consumables for each batch of cell therapy produced.
- Automated Manufacturing Units (AMUs): Sale of automated manufacturing unit equipment for modular scale-out. Equipment enables parallel processing and centralized control with electronic run records.
- GMP Manufacturing Platform: Technology transfer and GMP manufacturing support for transitioning from research use (RUO) to full GMP manufacturing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise B2B pricing for GMP-compatible manufacturing platform |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Avectas product offering
Product offeringCore offering
Avectas develops and sells the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single core consumable supported by modular Automated Manufacturing Units (AMUs). The company supplies both a GMP-grade manufacturing system for clinical/commercial cell therapy production and a research-use Solupore Integrated Research Tool (RT), along with the SoluPrime Knock-In Transfection Enhancer reagent, targeting biopharma developers, CDMOs, and academic research institutions.
Product overview
Avectas offers Solupore® Integrated as its core automated manufacturing platform for cell and gene therapies, consolidating multiple unit processes (activation, transduction, expansion, and harvest) into a single closed consumable. The platform is available in two variants: the GMP-grade Solupore® Integrated for clinical and commercial manufacturing, and the Solupore® Integrated Research Tool (RT) for discovery and translational workflows. SoluPrime Knock-In Transfection Enhancer is an add-on reagent that primes cells for improved knock-in efficiency when combined with electroporation delivery, extending the platform's genome editing capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Solupore Integrated: Automated, integrated and scalable cell therapy manufacturing platform that consolidates activation, transduction, expansion, and harvest into a single closed consumable system.
- Solupore Integrated Research Tool (RT)
- SoluPrime Knock-In Transfection Enhancer
Products and services
- Solupore® Integrated
Quantifiable outcome
- Facility cost reduction of 75% vs other integrated platforms
- +4 more outcomes
Companies that use Avectas
Customer profileSegments3 records
Ideal customer profiles3 records
Avectas technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Avectas partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, key and supporting.
- CCRMcoreCCRM and its CDMO subsidiary OmniaBio partnered with Avectas to evaluate Avectas' automated, integrated and scalable cell therapy manufacturing platform. The evaluation aims to complement CCRM's global network of advanced therapy hubs and improve automation, scalability and manufacturing efficiency. The partnership coincides with plans to establish CCRM Ireland, supported by a government MOU between Ireland and Canada for expanded life science collaboration.
- OmniaBiocoreCDMO subsidiary of CCRM partnering to evaluate Avectas' Solupore Integrated platform for cell therapy manufacturing, with focus on automation and scalability improvements.
- Thermo Fisher ScientifickeyCollaboration study demonstrating successful reprogramming of blood cell types using srRNA to produce functional iPSCs. First study to successfully demonstrate reprogramming using this method.
- Sony BiotechnologykeyApplication note collaboration demonstrating that Solupore Integrated transfected cells isolated using Sony's CGX10 yield highly cytotoxic CAR-T cells. Joint webinar hosted October 28, 2025.
- GenScriptsupportingApplication note on Solupore Integrated knock-in using GenScript GenExact single-stranded DNA, demonstrating integration capabilities.
- LumickssupportingApplication note demonstrating that Solupore Integrated provides superior cellular avidity, essential for optimizing cell therapy processes.
- ScalereadysupportingMultiple application notes demonstrating Solupore Integrated performance in Scaleready platforms, including enhanced stem cell memory and cytotoxic function in engineered T cells.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Avectas competitors and assessment
Company assessmentDirect peers
- Miltenyi Biotec: Privately held German life-science tools company whose Prodigy platform is the most established integrated, automated cell therapy manufacturing system. Direct competitor to Solupore Integrated for autologous CAR-T and other engineered cell therapy workflows at biopharma and CDMO customers.
- MaxCyte: US-listed company whose Flow Electroporation technology is a leading non-viral cell engineering platform used in clinical and commercial cell therapy manufacturing. Directly comparable core delivery modality to Solupore's non-viral mRNA/CRISPR/HDR workflows.
- Cellares: Well-funded startup commercializing the Cell Shuttle, a high-throughput automated cell therapy manufacturing platform positioned for both autologous and allogeneic workflows. Closest emerging-stage direct competitor to Solupore Integrated.
- Ori Biotech: UK/US company developing an automated, closed cell and gene therapy manufacturing platform (Iro) targeted at cell therapy developers and CDMOs. Directly comparable go-to-market and product positioning to Avectas.
Broad incumbents
- Lonza: Global CDMO and bioprocessing incumbent offering the Cocoon platform for automated, closed cell therapy manufacturing alongside a large contract manufacturing footprint. Competes with Avectas both as a platform vendor and as a service provider to the same biopharma customers.
- Thermo Fisher Scientific: Large life-science tools and bioprocessing supplier with a broad Cell Therapy Systems (CTS) portfolio of instruments, consumables, and reagents used in cell therapy manufacturing. Counts as a partner (collaboration study) and an incumbent competitor to Avectas in the same customer workflows.
- Cytiva: Global bioprocessing supplier (Danaher) offering instruments, consumables, and automation solutions across cell therapy and gene therapy manufacturing. Competes with Avectas as a broad incumbent in the same cell therapy manufacturing tool stack.
- Terumo BCT: Division of Terumo that provides cell processing systems, including the FINIA cell processing platform, used in cell and gene therapy manufacturing. Overlaps with Avectas in cell processing and is an established incumbent in apheresis/cell collection workflows.
Emerging players
- Multiply Labs: Early-stage company applying robotic automation to cell therapy manufacturing with a focus on modular, scalable production. Less mature and capital-light versus Avectas but overlapping product thesis and target customers.
Others
- ScaleReady: Cell and gene therapy manufacturing solutions provider (a GPG/CTC joint venture) offering the G-Rex bioreactor platform and process development support. Existing Avectas partner for joint application notes, but adjacent (reagents/process platform) rather than direct head-to-head competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Avectas social profiles
Digital presenceAvectas financial estimates
Financial estimateRevenue estimate
Valuation estimate
Avectas leadership team
Management profileNumber of profiles
Profiles11 records
Avectas funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Avectas M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Avectas
What does Avectas do?
Avectas develops and sells the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single core consumable supported by modular Automated Manufacturing Units (AMUs). The company supplies both a GMP-grade manufacturing system for clinical/commercial cell therapy production and a research-use Solupore Integrated Research Tool (RT), along with the SoluPrime Knock-In Transfection Enhancer reagent, targeting biopharma developers, CDMOs, and academic research institutions.
Is Avectas a public or private company?
Avectas is a private company. It is classified as venture growth investor backed and is currently operating.
When was Avectas founded?
Avectas was founded in 2010. It employs 11 to 50 people.
Where is Avectas based?
Avectas is headquartered in Maynooth, Ireland, in the Europe region.
How does Avectas make money?
Three revenue lines are on record. Solupore Integrated Consumables are the primary driver. The others are automated Manufacturing Units (AMUs) and GMP Manufacturing Platform.
Who are Avectas's main competitors?
Direct peers on record are Miltenyi Biotec, MaxCyte, Cellares and Ori Biotech. Broad incumbents are Lonza, Thermo Fisher Scientific, Cytiva and Terumo BCT. Multiply Labs is listed as an emerging player. ScaleReady is listed as an others.
Does Avectas have an API?
No public API is recorded for Avectas.
What industry is Avectas in?
Avectas's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 334510 and its SIC code is 3845.